Xueyang Li

机构：Xuzhou Medical College, Inner Mongolia University · ORCID：0000-0001-8161-4781

发表论文 71 篇 · 总被引 1427 次 · h-index 19

代表论文

• Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis (2023 · Journal of Experimental & Clinical Cancer Research · 被引 81)
• Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy (2024 · Gastroenterology · 被引 46)
• SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation (2023 · Gut · 被引 44)
• Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding (2024 · Cancer · 被引 29)
• Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: A prospective cohort study (2022 · Journal of clinical lipidology · 被引 21)
• CD64 + fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8 + T cells (2024 · Gut · 被引 17)